Despite being a relatively new company, in 2019, we raised the most money in our field in China. We are really one of the frontrunners in…
In Conversation
It is lamentable that some of the lessons of the previous H1N1 pandemic were forgotten as the world tried to cope with the COVID-19 outbreak. In…
Fundamentally, we need to keep an open mind about learning from existing models, yet should avoid simply copying and pasting what has worked in other countries…
JLABS @ Shanghai is a no-strings-attached incubator, which means entrepreneurs are free to develop their science while holding on to their intellectual property - providing a…
The core business – our research-driven, data-driven approach to innovation – has not changed [post-IPO]. We are committed to developing our portfolio and generating value for…
Before the IPO, we might have been seen as a mostly Chinese company working on interesting science and products, but now we are evidently a globally-ready…
From the time of Harbour BioMed’s inception in 2016, we have always set out to be a patient-centric global biotech company with multiple forms of value…
Even though lab animals make up only a limited portion of the total cost of new drug development, they are very important for every R&D process…
I am at a stage where I have a different perspective, which allows me to conduct R&D in a different way - doing disruptive innovation
The current hot topic is China’s focus on ensuring that healthcare innovation does not only depend on foreign innovation but how it can be translated and…
Our animal facility is the first one in China to earn AAALAC accreditation and has maintained it for 13 years. We adhere to strict international standards. Our…
By having a manufacturing facility in the USA or Europe, our foreign customers will be more comfortable when relying on us – in particular, bigger companies…
